98% SVR12 in Korean and Taiwanese Patients With Chronic Genotype 2 HCV Infection Receiving 12 Weeks of Sofosbuvir Plus Ribavirin: Results From an International, Multicenter Phase 3 Study

Press/Media: Press / Media

Period2015 May 1

Media coverage

1

Media coverage

  • Title98% SVR12 in Korean and Taiwanese Patients With Chronic Genotype 2 HCV Infection Receiving 12 Weeks of Sofosbuvir Plus Ribavirin: Results From an International, Multicenter Phase 3 Study
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date15/5/1
    URLwww.natap.org/2015/EASL/EASL_94.htm
    PersonsSangHoon Ahn